Loading organizations...
Alderline Group is a private investment partnership focused on providing funding and strategic support to emerging technology and healthcare enterprises, operating from an undisclosed headquarters location. The firm operates by taking equity positions in promising companies across these two primary sectors, aiming to generate returns through long-term asset appreciation and strategic growth initiatives. Because the organization functions as a strictly private entity, specific financial metrics regarding its total assets under management, current portfolio valuation, and overall employee count remain publicly undisclosed. The firm leverages the extensive corporate leadership experience of its executive team to guide portfolio companies, notably drawing on the expertise of former Johnson and Johnson Chairman and Chief Executive Officer Alex Gorsky. Alderline Group was co-founded by Alex Gorsky during an undisclosed year to pursue targeted private investments across the broader healthcare and technology landscapes.
Alderline Group primarily targets healthcare innovation and technology solutions, with a particular focus on companies within the biotechnology, life science, and pharmaceutical industries.
Alderline Group participates as an investor in financing rounds for companies, such as its involvement in Parabilis Medicines' oversubscribed $305 million financing to support clinical development.
Alderline Group operates as an investment firm within the Venture Capital and Private Equity Principals industry.
Alderline Group primarily targets healthcare innovation and technology solutions, with a particular focus on companies within the biotechnology, life science, and pharmaceutical industries.
Alderline Group participates as an investor in financing rounds for companies, such as its involvement in Parabilis Medicines' oversubscribed $305 million financing to support clinical development.
Alderline Group operates as an investment firm within the Venture Capital and Private Equity Principals industry.
Alderline Group, founded in 2022, operates as an investment firm with a dedicated focus on the healthcare sector. The firm's investment mandate is specifically directed towards companies engaged in healthcare innovation and technology solutions. This includes a broad range of enterprises within the biotechnology, life science, and pharmaceutical industries, reflecting a strategic interest in advancements that can impact medical treatment and patient care.
The firm functions within the venture capital and private equity landscape, indicating its involvement in both early-stage and more mature companies. Its role typically involves providing capital to support the development, expansion, and commercialization of new technologies and therapies. This financial backing is crucial for companies operating in research-intensive and capital-intensive sectors like biotechnology and pharmaceuticals.
Alderline Group has been noted for its participation in significant financing rounds. For instance, the firm was among the investors in Parabilis Medicines' oversubscribed $305 million financing. This involvement underscores Alderline Group's commitment to supporting companies that are advancing clinical development and pioneering new pipelines in areas such as oncology.
By concentrating its investment efforts on healthcare innovation, Alderline Group aims to contribute to the growth of companies that are developing novel solutions. Its investment activities are designed to foster progress in areas that can lead to new medical breakthroughs and improved healthcare outcomes.
Alderline Group has 1 tracked investment across 1 company. The latest tracked deal is $52.0M Series A in Third Arc Bio in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 4, 2026 | Third Arc Bio | $52.0M Series A | Andreessen Horowitz | AbbVie, Aberdeen Investments, Biotechnology Value Fund, Galapagos, Goldman Sachs Alternatives, Hillhouse Investment, Marshall Wace, Omega Funds, T. Rowe Price, Abrdn, BVF Partners, Freepoint Capital Group, 高盛 |
